NASDAQ:CRIS Curis (CRIS) Stock Price, News & Analysis → Don’t make this retirement mistake (From Sasco Gold LLC) (Ad) Free CRIS Stock Alerts $8.00 -0.84 (-9.50%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$6.32▼$8.8450-Day Range$8.00▼$16.8052-Week Range$3.80▼$18.00Volume231,878 shsAverage Volume28,211 shsMarket Capitalization$47.12 millionP/E RatioN/ADividend YieldN/APrice Target$37.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Curis alerts: Email Address Curis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside366.7% Upside$37.33 Price TargetShort InterestHealthy1.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($5.39) to ($4.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector697th out of 904 stocksBiological Products, Except Diagnostic Industry120th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingCuris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCuris has only been the subject of 3 research reports in the past 90 days.Read more about Curis' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.11% of the float of Curis has been sold short.Short Interest Ratio / Days to CoverCuris has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Curis has recently decreased by 2.97%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCuris does not currently pay a dividend.Dividend GrowthCuris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRIS. Previous Next 0.6 News and Social Media Coverage Search Interest1 people have searched for CRIS on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Curis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.70% of the stock of Curis is held by insiders.Percentage Held by InstitutionsOnly 29.97% of the stock of Curis is held by institutions.Read more about Curis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Curis are expected to grow in the coming year, from ($5.39) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Curis is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Curis is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCuris has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Curis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCDon’t make this retirement mistakeIf you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it.Reserve your seat here. About Curis Stock (NASDAQ:CRIS)Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Read More CRIS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRIS Stock News HeadlinesMay 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Curis’s Emavusertib Following Promising Leukemia Study ResultsMay 14, 2024 | prnewswire.comCuris Announces Additional Data from TakeAim Leukemia StudyMay 10, 2024 | prnewswire.comCuris to Present Updated Data from the TakeAim Leukemia StudyMay 8, 2024 | markets.businessinsider.comCuris Buy Rating Affirmed on Strong Earnings and Promising Emavusertib TrialsMay 8, 2024 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | investorplace.comCRIS Stock Earnings: Curis Beats EPS, Misses Revenue for Q1 2024May 7, 2024 | finanznachrichten.deCuris, Inc.: Curis Provides First Quarter 2024 Business UpdateMay 7, 2024 | markets.businessinsider.comCuris Inc Q1 Loss beats estimatesMay 7, 2024 | washingtonpost.comCuris: Q1 Earnings SnapshotMay 7, 2024 | prnewswire.comCuris Provides First Quarter 2024 Business UpdateApril 30, 2024 | prnewswire.comCuris to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024April 23, 2024 | finance.yahoo.comCuris, Inc. (CRIS)April 18, 2024 | finance.yahoo.comCuris, Inc. (CRIS) Interactive Stock Chart - Yahoo FinanceApril 5, 2024 | prnewswire.comCuris Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)April 4, 2024 | prnewswire.comCuris to Present at Upcoming Healthcare Conferences in AprilApril 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)March 28, 2024 | finance.yahoo.comCuris, Inc. (CRIS) Stock Historical Prices & Data - Yahoo FinanceFebruary 24, 2024 | benzinga.comCuris Stock (NASDAQ:CRIS) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comCuris Stock (NASDAQ:CRIS), Analyst Ratings, Price Targets, PredictionsFebruary 10, 2024 | msn.comCuris Inc. Is Worried About This – Should You Be Worried Too?February 9, 2024 | finance.yahoo.comCuris, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call TranscriptFebruary 8, 2024 | finanznachrichten.deCuris, Inc.: Curis Provides Fourth Quarter 2023 Business UpdateFebruary 8, 2024 | markets.businessinsider.comCuris Inc Q4 sales declineFebruary 8, 2024 | finance.yahoo.comCuris Provides Fourth Quarter 2023 Business UpdateFebruary 7, 2024 | benzinga.comCuris's Earnings: A PreviewSee More Headlines Receive CRIS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today6/11/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:CRIS CUSIP23126910 CIK1108205 Webwww.curis.com Phone(617) 503-6500Fax617-503-6501Employees49Year Founded2000Price Target and Rating Average Stock Price Target$37.33 High Stock Price Target$60.00 Low Stock Price Target$26.00 Potential Upside/Downside+366.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($8.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,410,000.00 Net Margins-486.45% Pretax Margin-486.45% Return on Equity-224.75% Return on Assets-60.88% Debt Debt-to-Equity RatioN/A Current Ratio4.08 Quick Ratio4.08 Sales & Book Value Annual Sales$9.81 million Price / Sales4.81 Cash FlowN/A Price / Cash FlowN/A Book Value$3.34 per share Price / Book2.40Miscellaneous Outstanding Shares5,894,000Free Float5,558,000Market Cap$47.15 million OptionableNo Data Beta3.44 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. James E. Dentzer (Age 57)President, CEO, Secretary, Treasurer & Director Comp: $1.07MMs. Diantha Duvall CPA (Age 52)M.B.A., CFO and Principal Financial & Accounting Officer Comp: $719.02kDr. Jonathan B. Zung Ph.D. (Age 58)Chief Development Officer Comp: $691.27kMr. Mark W. Noel (Age 65)Vice President of Technology Management & Intellectual Property Comp: $279.28kMs. Elif McDonaldVP of Investor Relations & Corporate CommunicationsDr. Reinhard Wilhelm von Roemeling M.D.Senior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsCidara TherapeuticsNASDAQ:CDTXNeon TherapeuticsNASDAQ:NTGNX4 PharmaceuticalsNASDAQ:XFORAchieve Life SciencesNASDAQ:ACHVRigel PharmaceuticalsNASDAQ:RIGLView All CompetitorsInstitutional OwnershipCM Management LLCBought 95,000 shares on 5/14/2024Ownership: 2.037%Vanguard Group Inc.Bought 10,097 shares on 5/10/2024Ownership: 3.708%Focused Wealth Management IncBought 14,656 shares on 5/8/2024Ownership: 0.563%Franklin Street Advisors Inc. NCBought 20,128 shares on 4/16/2024Ownership: 0.342%Kingdon Capital Management L.L.C.Sold 25,000 shares on 3/18/2024Ownership: 4.824%View All Institutional Transactions CRIS Stock Analysis - Frequently Asked Questions Should I buy or sell Curis stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRIS shares. View CRIS analyst ratings or view top-rated stocks. What is Curis' stock price target for 2024? 3 analysts have issued 12-month target prices for Curis' stock. Their CRIS share price targets range from $26.00 to $60.00. On average, they predict the company's stock price to reach $37.33 in the next year. This suggests a possible upside of 366.7% from the stock's current price. View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts. How have CRIS shares performed in 2024? Curis' stock was trading at $12.75 at the beginning of 2024. Since then, CRIS stock has decreased by 37.3% and is now trading at $8.00. View the best growth stocks for 2024 here. When is Curis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CRIS earnings forecast. How were Curis' earnings last quarter? Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings data on Tuesday, May, 7th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.94) by $0.11. The biotechnology company earned $2.09 million during the quarter, compared to analysts' expectations of $2.31 million. Curis had a negative net margin of 486.45% and a negative trailing twelve-month return on equity of 224.75%. During the same period in the previous year, the firm posted ($2.40) EPS. When did Curis' stock split? Curis's stock reverse split before market open on Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Curis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK). Who are Curis' major shareholders? Curis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.71%), CM Management LLC (2.04%), Focused Wealth Management Inc (0.56%), Franklin Street Advisors Inc. NC (0.34%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Curis? Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRIS) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Curis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Curis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.